Fed-up and demoralized, FDA staff are leaving.
This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.
Related Articles
Claims of Microsoft’s ‘super-intelligent’ AI diagnosis agent miss the mark, say experts
Hype around a Microsoft AI agent’s ability to diagnose difficult cases misses the mark and overlooks real innovation, experts say.
Male and female athletes have different hearts, and that can have serious consequences
When female athletes collapse on the playing field, they are less likely to be resuscitated than men: How gender differences play out in sports medicine.
ER docs are too quick to assume cannabis users are experiencing this rare side effect
Pervasive stigma around cannabis use is leading some ER doctors to overdiagnose a rare marijuana-related syndrome.
Pharmalittle: We’re reading about Medicare drug negotiations, a Novartis malaria drug, and more
The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug price negotiations
Pharmalittle: We’re reading about Medicare drug negotiations, a Novartis malaria drug, and more
The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug price negotiations
Novartis wins approval for newborn malaria treatment
And other biotech news, brought to you by The Readout.
ER docs are too quick to assume cannabis users are experiencing this rare side effect
Pervasive stigma around cannabis use is leading some ER doctors to overdiagnose a rare marijuana-related syndrome.
Male and female athletes have different hearts, and that can have serious consequences
When female athletes collapse on the playing field, they are less likely to be resuscitated than men: How gender differences play out in sports medicine.
How Republicans sidelined the health care industry and pushed through historic Medicaid cuts
The passage of President Trump’s signature tax cut bill shows how the health care industry’s influence is waning.
Inside the staff exodus and tanking morale that threaten Makary’s FDA
FDA staff are struggling and missing deadlines, and the future consequences could be even more dire.
